

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 93811

Title: Efficacy of fexuprazan compared with rebamipide in Korean patients with gastritis:

A matching-adjusted indirect comparison

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06636742 Position: Peer Reviewer Academic degree: MD

Professional title: Attending Doctor

Reviewer's Country/Territory: Serbia

Author's Country/Territory: South Korea

Manuscript submission date: 2024-03-18

Reviewer chosen by: AI Technique

Reviewer accepted review: 2024-03-25 21:31

Reviewer performed review: 2024-04-02 16:11

Review time: 7 Days and 18 Hours

| Scientific quality Good | |
|---|-----|
| [] Grade D: Fair [] Grade E: Do not publish | ļ |
| Novelty of this manuscript [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fa | ıir |
| Creativity or innovation of [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fa | ıir |
| this manuscript [] Grade D: No creativity or innovation | |



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

| Scientific significance of the conclusion in this manuscript | [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance |
|--|---|
| Language quality | [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection |
| Conclusion | [] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection |
| Re-review | [Y] Yes [] No |
| Peer-reviewer statements | Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No |

SPECIFIC COMMENTS TO AUTHORS

The aim of the study was to compare the efficacy of the novel P-CAB fexuprazan with rebamipide for acute and chronic gastritis. The study is well and precisely written. P-CABs are emerging class of drugs and more data are greatly needed about their efficacy and safety profile, especially data extracted from comparison of novel medications like fexuprazan and other drugs for acid-related disorders. Therefore, this study would be of great importance for the readers of WJG.